Back HCV Treatment

ICAAC 2014: AbbVie 3D Regimen Shows High Cure Rates for Genotype 1b HCV Patients

AbbVie's interferon-free 3D regimen containing ABT-450, ombitasvir, and dasabuvir led to sustained virological response in nearly 100% of people with genotype 1b chronic hepatitis C regardless of unfavorable patient or viral characteristics, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.


Read more: